Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | ATR | Q13535 | 14/20 | 0.44 |
| ▸ | ATM | Q13315 | 7/20 | 0.44 |
| ▸ | GSK3B | P49841 | 3/20 | 0.44 |
| ▸ | PRKDC | P78527 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL668030 | 0.92 | L3MBTL1 (0.40) | L3MBTL1ATRATMGSK3BPRKDC | |
| SCHEMBL664890 | 0.89 | ATR (0.56) | ATRATMGSK3BPRKDCMAPT | |
| SCHEMBL14375195 | 0.87 | ATR (0.41) | L3MBTL1ATRATMGSK3BPRKDC | |
| SCHEMBL665615 | 0.85 | ATR (0.40) | L3MBTL1ATRATMGSK3BPRKDC | |
| SCHEMBL667102 | 0.84 | ATR (0.41) | L3MBTL1ATRATMGSK3BPRKDC | |
| SCHEMBL10173334 | 0.84 | ATR (0.39) | ATRATMGSK3BPRKDC | |
| SCHEMBL667758 | 0.82 | ATR (0.39) | ATRATMGSK3BPRKDC | |
| SCHEMBL14332008 | 0.82 | ATR (0.47) | ATRATMGSK3BPRKDCALDH1A1 | |
| SCHEMBL667591 | 0.80 | ATR (0.38) | ATRATMGSK3BPRKDC | |
| SCHEMBL12400208 | 0.80 | JAK2 (0.49) | L3MBTL1ALDH1A1LMNAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046295-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-23 | — | — | US | disclosed |
| WO-2011163527-A1 | PYRROLO- PYRAZINE DERIVATIVES USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046295-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | L3MBTL1 3454/4885ATR 1/4885ATM 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.